Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5Tumor-Agnostic 2Head & Neck 2Thoracic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 77Kidney Neoplasms 23Prostatic Neoplasms 22Neoplasm Metastasis 13Colorectal Neoplasms 10Neoplasms 8Melanoma 7Carcinoma, Transitional Cell 6Breast Neoplasms 6Urinary Bladder Neoplasms 5Stomach Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Urologic Neoplasms 2Triple Negative Breast Neoplasms 2Myeloproliferative Disorders 2Multiple Myeloma 2Hereditary leiomyomatosis and renal cell cancer 2Hematologic Neoplasms 2Financial Stress 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2

Interventions

pembrolizumab 7padeliporfin 5Nivolumab 4Everolimus 4Sunitinib 3Sorafenib 3Mitomycin 3fludarabine 2epothilone B 2durvalumab 2cabozantinib 2Ipilimumab 2Cyclophosphamide 2Cisplatin 21-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2volociximab 1vinflunine 1sipuleucel-T 1sargramostim 1pemigatinib 1palladium-bacteriopheophorbide 1palbociclib 1obinutuzumab 1luprolide acetate gel depot 1lenvatinib 1ixabepilone 1fludarabine phosphate 1enzalutamide 1belzutifan 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Bevacizumab × Genitourinary × Clear all
NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡